# Lantheus Medical Imaging — Hazardous Materials Safety Interpretation

**Citation:** 08-0282  
**Type / status:** guidance / guidance  
**Agency:** Pipeline and Hazardous Materials Safety Administration  
**Effective:** Not stated  
**Published:** 2009-01-14

08-0282 response to Lantheus Medical Imaging concerning 173.435.

## Document text

<<<PAGE 1>>>

U.S. Department
of Transportation
Pipeline and Hazardous Materials
Safety Administration
1200 New Jersey Ave., SE
Washington, DC 20590
Mr. Kevin Anderson
Lantheus Medical Imaging
Building 200-2
33 1 Treble Cove Road
Billerica, MA 01 862
Ref. No. 08-0282
Dear Mr. Anderson:
This responds to your November 10,2008 letter requesting clarification of the Hazardous
Materials Regulations (HMR; 49 CFR Parts 171 -1 80). Specifically, you ask for clarification
of footnote (i) to the table of A1 and A2 values for radionuclides in 5 173.435. Footnote (i)
provides that A2 = 0.74 TBq (20 Ci) for Molybdenum (Mo-99) for domestic use. You ask if
this A2 value may be used for the domestic portion of an international shipment from the
United States to Canada.
The answer is yes. The A2 value (A2 = 0.74 TBq (20 Ci)) authorized by footnote (i) to the
table of A1 and A2 values for radionuclides in 5 173.435 permits the use of that value for any
domestic transportation of Mo-99 including the domestic portion of an international
shipment. Note that the shipment to Canada must also comply with the Transport of
Dangerous Goods (TDG) regulations, which govern the transportation of hazardous materials
in Canada.
I hope this information is helpful. Please contact us if you require additional assistance.
arles E. Betts,
Development
Materials Standards

<<<PAGE 2>>>

Lantheus
Medical Imaging
331 Treble Cove Road 800.362.2668
North Billerica. MA 01862 www.lantheus.com
October 29, 2008
U.S. Department of Transportation
Office of Hazardous Materials Technology
Attn: Richard Boyle, PHH-23
1200 New Jersey Avenue
SE East Bldg. 200, 2"d Floor
Washington, D.C. 20590
Dear Mr. Boyle,
This letter is a follow up to our telephone conversation on October 27, 2008.
I would like to make shipments, originating in the U.S., containing 20 curies of
Molybdenum-99 (Mo-99) into Canada.
As per the U.S. D.O.T. regulations, 91 73.435, the maximum amount of Mo-99 allowed
during ground transportation is 20 curies for a domestic shipment. Does the word
"domestic" imply that shipments going into Canada must follow the maximum
requirements of 16.2 curies for non-domestic shipments?
The Canadian Nuclear Safety and Control Act, Section 2 (d) allows for 21 curies of Mo-
99 to be transported during a ground transportation shipment. Additionally, Transport
Canada Regulations, Section 9.1 recognizes U.S. D.O.T. 49 CFR regulations for ground
transportation.
With regards to U.S. D.O.T., is it acceptable to transport 20 curies of Mo-99 into
Canada?
Thank you for your help in this matter.
Sincerely,
Kevin Anderson
Senior Transportation Compliance Officer

## Provenance

- Official: Yes
- Source: <https://www.phmsa.dot.gov/sites/phmsa.dot.gov/files/legacy/interpretations/Interpretation%20Files/2008/080282.pdf>
- Source ID: `phmsa`
- SHA-256: `76e0cbd3ed276256218ffeb63d90ca85f619956c1f3efa69a674077fc5582e28`
- Retrieved: 2026-08-20T00:59:31.977Z
- Exported: 2026-08-24T01:00:48.963Z
- Document slug: `phmsa-interpretation-08-0282`

### Source metadata

```json
{
  "materialSubtype": "interpretation",
  "interpretationArea": "hazardous_materials",
  "representation": "full_text_from_official_pdf",
  "companies": [
    "Lantheus Medical Imaging"
  ],
  "individuals": [
    "Mr. Kevin Anderson"
  ],
  "refIds": [
    "08-0282"
  ],
  "catalogDates": [
    "2009-01-14"
  ],
  "catalogParts": [
    173
  ],
  "catalogRowCount": 1,
  "sourceRecordUrls": [
    "https://www.phmsa.dot.gov/node/67231"
  ],
  "linkedAttachmentUrls": [],
  "unavailableResponseUrls": [],
  "duplicateRepresentationUrls": [],
  "citedSections": [
    "173.435"
  ],
  "catalogPageUrls": [
    "https://www.phmsa.dot.gov/regulations/title49/section/173435"
  ],
  "pdfUrls": [
    "https://www.phmsa.dot.gov/sites/phmsa.dot.gov/files/legacy/interpretations/Interpretation%20Files/2008/080282.pdf"
  ],
  "representations": [
    {
      "viewUrl": "https://www.phmsa.dot.gov/sites/phmsa.dot.gov/files/legacy/interpretations/Interpretation%20Files/2008/080282.pdf",
      "detailUrl": null,
      "detailHtmlPath": null,
      "pdfUrl": "https://www.phmsa.dot.gov/sites/phmsa.dot.gov/files/legacy/interpretations/Interpretation%20Files/2008/080282.pdf",
      "pdfArtifactPath": "data/sources/phmsa-interpretations/08-0282-0dbf870454.pdf",
      "pdfArtifactSha256": "896f4bf3e8e1095d1177daf8fdd0db79a70a3bddfce97e4e9127b4e4e30ac184",
      "extractedTextPath": "data/sources/phmsa-interpretations/08-0282-0dbf870454.v2.txt",
      "extractedTextSha256": "f8df8579e58902908fa4e2dc7d2611731528a9065b02d3e54b7599fc6f024469",
      "pageCount": 2,
      "extractionVersion": 2
    }
  ],
  "caveat": "Interpretations apply regulations to the facts presented and do not create independently enforceable requirements.",
  "jurisdiction": "US"
}
```